Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...

HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ongoing 13th ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...